LARGE B-CELL LYMPHOMA (LBCL)
Clinical trials for LARGE B-CELL LYMPHOMA (LBCL) explained in plain language.
Never miss a new study
Get alerted when new LARGE B-CELL LYMPHOMA (LBCL) trials appear
Sign up with your email to follow new studies for LARGE B-CELL LYMPHOMA (LBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
AI takes on lymphoma: personalized treatment strategy under trial
Disease control Not yet recruitingThis study compares an AI-driven treatment strategy to standard therapy (Pola-R-CHP) for people with previously untreated large B-cell lymphoma. About 178 participants will be grouped by risk using an AI model, and those at intermediate or high risk will receive either a personal…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope: drug may prevent dangerous reactions to cancer immunotherapy
Disease control Not yet recruitingThis study tests whether the drug emapalumab can prevent severe side effects (cytokine release syndrome and nerve-related toxicity) in people with lymphoma or multiple myeloma receiving bispecific antibody therapy. About 60 adults will take emapalumab before their cancer treatmen…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Experimental CAR-T therapy takes on tough lymphoma
Disease control Not yet recruitingThis early-phase trial is testing a new type of immune cell therapy called CD19X CAR-T for people with large B-cell lymphoma that has come back or not responded to other treatments. Only 3 participants will receive the therapy after a short course of chemotherapy to prepare their…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for hard-to-treat lymphoma: three-drug combo enters early trials
Disease control Not yet recruitingThis early-phase trial tests whether combining three drugs (golcadomide, poseltinib, and rituximab) can shrink or control tumors in people with relapsed or refractory large B-cell lymphoma. About 20 adults will take part. The goal is to see if the combination works better than cu…
Matched conditions: LARGE B-CELL LYMPHOMA (LBCL)
Phase: PHASE1, PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC